Apellis Pharmaceuticals Inc (APLS)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$25.21
Buy
$26.20
$0.265 (+1.06%)
Prices updated at 12 Dec 2025, 22:53 EST
| Prices minimum 15 mins delay
Prices in USD
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 397m | 781m | |
| 338m | 664m | |
| -517m | -165m | |
| -130.39 | -21.11 | |
| -529m | -198m | |
| -495m | -155m | |
| Sales, General and administrative | 501m | 501m |
| Interest expenses | 30m | 40m |
| Provision for income taxes | 2m | 1m |
| Operating expenses | 855m | 829m |
| Income before taxes | -526m | -197m |
| Net income available to common shareholders | -529m | -198m |
| -4.45 | -1.6 | |
| Net interest income | -9m | -28m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -4.45 | -1.6 |
| Free cash flow per share | -5.5084 | -1.6703 |
| Book value/share | 1.9428 | 1.9047 |
| Debt equity ratio | 0.53715 | 2.026048 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 766m | 789m |
| Current liabilities | 248m | 186m |
| Total capital | 288m | 681m |
| Total debt | 111m | 470m |
| Total equity | 195m | 229m |
| Total non current liabilities | - | - |
| Loans | 93m | 453m |
| Total assets | 789m | 885m |
| Total liabilities | - | - |
| Cash and cash equivalents | 351m | 411m |
| Common stock | 120m | 124m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 553m | 352m |
| Cash dividends paid | - | - |
| -596m | -88m | |
| Investments (gains) losses | -674,000 | -403,000 |
| 352m | 413m | |
| Net income | - | - |
| -595m | -88m | |
| -773,000 | -403,000 |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
